How one US state is tackling the drug affordability crisis
Drug affordability remains a key priority for the US government as it negotiates with pharma companies to lower individual drug…
All articles by Manasi Vaidya
Manasi Vaidya
@manasivaidya22
Manasi Vaidya is an editor for GlobalData Insights where she covers the healthcare space. She writes and edits features that look at the research, regulation and reimbursement of drugs with a focus on topics at the intersection of business and science.
-
-
States consider payment limits to curb prescription drug prices with PDABs
Four weeks into her pregnancy, Jessica Intermill sensed something was wrong when the pain in her fingers wouldn’t subside. What…
-
Podcast: US tariff news and Q2 earnings influence pharma trends
After months of negotiations, the EU and US reached an agreement to levy a 15% tariff on EU imports, which…
-
Uncertainty around tariffs is a disincentive for pharma onshoring in the US
Marking another chapter in the narrative around US tariffs, a new agreement signed in the last fortnight between the European…
-
Trump doubles down on Most Favored Nation plan to target drug prices
US President Donald Trump has called on pharmaceutical manufacturers to lower US drug prices in line with the Most Favored…
-
Farxiga and Jardiance pose affordability issues, says Maryland drug board
Maryland’s prescription drug affordability board (PDAB) passed resolutions affirming that Eli Lilly and Boehringer Ingelheim’s Jardiance (empagliflozin) and AstraZeneca’s Farxiga…
-
Can rare disease research in the US thrive under the new administration?
In 2024, 50% of the novel drugs approved by the FDA had an orphan drug designation. In the last two…
-
FDA Commissioner envisions fewer delays, more clinical trial flexibility and AI use
US Food and Drug Administration (FDA) Commissioner Dr. Marty Makary addressed concerns about the recent cuts impacting the agency’s ability…
-
FDA creates new priority review voucher scheme to boost US interests
The US Food and Drug Administration (FDA) has created a new priority review voucher (PRV) framework to expedite the drug…
-
European biotech ecosystem takes aim at changing the funding narrative
“The science is brilliant in Europe, but the translation is what’s lacking,” said V-Bio Ventures managing partner Christina Takke on…